Stockscreener 앱 받기
2.29
0.43%
-0.010
시간 외 거래:
2.30
0.010
+0.44%
전일 마감가:
$2.30
열려 있는:
$2.27
하루 거래량:
52,382
Relative Volume:
0.42
시가총액:
$36.76M
수익:
$3.86M
순이익/손실:
$-19.20M
주가수익비율:
-3.1465
EPS:
-0.7278
순현금흐름:
$-24.88M
1주 성능:
-6.91%
1개월 성능:
-8.03%
6개월 성능:
-34.01%
1년 성능:
-56.15%
1일 변동 폭
$2.22
$2.34
1주일 범위
$2.22
$2.47
52주 변동 폭
$2.10
$7.40
Veru Inc Stock (VERU) Company Profile
명칭
Veru Inc
전화
(312) 595-9123
주소
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.29 | 36.92M | 3.86M | -19.20M | -24.88M | -0.7278 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Canaccord Genuity | Buy |
| 2024-05-14 | 개시 | B. Riley Securities | Buy |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2023-06-07 | 업그레이드 | Jefferies | Underperform → Hold |
| 2021-04-13 | 개시 | Jefferies | Buy |
| 2021-02-09 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2018-07-03 | 개시 | Maxim Group | Buy |
모두보기
Veru Inc 주식(VERU)의 최신 뉴스
Veru Inc. Amends 2018 Equity Incentive Plan and Reports Annual Meeting Results – Form 8-K Filing March 12, 2026 - Minichart
Veru Shareholders Expand Equity Plan, Reelect Board Leadership - TipRanks
Veru (NASDAQ: VERU) investors back larger equity plan, board slate and auditor - Stock Titan
Aug Macro: Is Veru Inc attractive for institutional investors2026 Opening Moves & Daily Market Momentum Tracking - baoquankhu1.vn
Veru Inc. (NASDAQ: VERU) Q1 2026 earnings call transcript - MSN
Veru Targets GLP-1 Muscle Loss Risk With New Enobosarm Combo Study - TipRanks
Veru enrolls first patient in obesity drug combination trial By Investing.com - Investing.com Canada
Veru (VERU) Launches Phase 2b Trial for Obesity Treatment - GuruFocus
Veru enrolls first patient in Phase 2b PLATEAU trial of enobosarm - TipRanks
Veru enrolls first patient in obesity drug combination trial - Investing.com Australia
Veru Inc. Initiates Phase 2b Clinical Trial for Enobosarm to Enhance Weight Loss in Older Patients with Obesity Receiving Semaglutide - Quiver Quantitative
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss - Yahoo Finance
VERU Earnings History & Surprises | EPS & Revenue Results | VERU INC (NASDAQ:VERU) - ChartMill
Veru Inc. (VERU) Presents at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceSlideshow - Seeking Alpha
Veru : Corporate Presentation, February 2026 - marketscreener.com
VERU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VERU Should I Buy - Intellectia AI
Veru at Oppenheimer Conference: Strategic Insights into Obesity Drug Development - Investing.com
VERU PE Ratio & Valuation, Is VERU Overvalued - Intellectia AI
Aug Volume: Is CHGG vulnerable to short sellersJuly 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Bitget
Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave - Intellectia AI
Will Veru Inc. benefit from sector rotationWeekly Trend Summary & Long-Term Capital Growth Strategies - mfd.ru
Aug Closing: Can PIII outperform under higher oil pricesAnalyst Downgrade & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com Nigeria
Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves - MSN
Veru Q1 2026 earnings preview - MSN
Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript - Insider Monkey
Veru Q1 2026 Earnings Call Transcript - MarketBeat
Veru Inc. Charts Risky but Clearer Post-GLP-1 Path - TipRanks
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. (VERU) Advances Clinical Pipeline with Enobosarm and S - GuruFocus
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Adva - GuruFocus
VERU INC. SEC 10-Q Report - TradingView
VERU: No revenue, $5.3M net loss, $33M cash, strategic shift to drug development, going concern risk - TradingView
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts By Investing.com - Investing.com South Africa
Veru (VERU) Q1 2026 Earnings Call Transcript - The Globe and Mail
VERU: Net loss narrowed, cash reserves rose, and enobosarm advances with FDA support for new trials - TradingView
Veru reports Q1 EPS (26c) vs. (61c) last year - TipRanks
VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline - ChartMill
Veru Inc. Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - TradingView
VERU: Q1 net loss narrowed, cash rose, and new enobosarm/semaglutide trial to launch soon - TradingView
Veru (NASDAQ: VERU) narrows loss as enobosarm obesity program advances - Stock Titan
Veru Inc. Advances Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide for Weight Management in Older Adults with Obesity - Quiver Quantitative
Veru tests enobosarm to help older semaglutide users beat weight-loss plateau - Stock Titan
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - The Manila Times
A Look at Veru's Upcoming Earnings Report - Benzinga
Veru (VERU) price target increased by 11.11% to 25.50 - MSN
Veru Inc. (VERU.US) is scheduled to release its earnings report before the market opens on February 11. - 富途牛牛
Veru (VERU) Price Target Increased by 11.11% to 25.50 - Nasdaq
Veru Inc. to Host Conference Call for Fiscal 2026 First Quarter Financial Results and Business Update - Quiver Quantitative
Veru Inc (VERU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):